Who Buys Irinotecan from India — 495 Importers Behind a $41.1M Market

The importation of Irinotecan from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like Fresenius Kabi Deutschland GmbH (Germany) and Yusen Logistics Benelux Belgium (Belgium) function as intermediaries, procuring large quantities to supply to healthcare providers. Their purchasing patterns are characterized by bulk orders and consistent procurement schedules to maintain a steady supply chain.

• Hospital Groups: Organizations such as Pharmacie Centrale des Hôpitaux (Algeria) represent centralized procurement bodies for hospital networks. They typically engage in large-volume purchases, often through tender processes, to meet the collective needs of associated hospitals.

• Contract Manufacturers: Companies like Eugia Pharma Inc (Canada) and Eugia US LLC (United States) specialize in manufacturing pharmaceuticals on behalf of other firms. They import active pharmaceutical ingredients (APIs) like Irinotecan for formulation and packaging, adhering to stringent quality standards. Their procurement is project-based, aligning with production schedules and client demands.

• Re-exporters: Entities such as Alloga France (Netherlands) and Accord Healthcare Polska Sp. z o.o. (Poland) import pharmaceuticals with the intent to distribute them to other markets. Their purchasing behavior is influenced by global demand fluctuations and regulatory considerations in target markets.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

Importing Irinotecan into the top five importing countries involves navigating specific regulatory frameworks:

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Requires submission of a marketing authorization application, including comprehensive data on quality, safety, and efficacy.
• Estimated Timeline: Approximately 7 months, subject to completeness and compliance of the application.
• Import Tariff/Duty: As an EU member, Germany applies a standard tariff rate of 0% for pharmaceuticals under HS Code 30049049.

• Poland:
• Regulatory Authority: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).
• Import Registration Process: Involves obtaining a marketing authorization, necessitating submission of detailed documentation on the medicinal product.
• Estimated Timeline: Typically 7 months, depending on the application's complexity and accuracy.
• Import Tariff/Duty: As part of the EU, Poland imposes a 0% tariff on pharmaceuticals classified under HS Code 30049049.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Requires a marketing authorization, with submission of extensive data on the product's quality, safety, and efficacy.
• Estimated Timeline: Approximately 7 months, contingent upon the thoroughness of the application.
• Import Tariff/Duty: As an EU member state, the Netherlands applies a 0% import tariff for pharmaceuticals under HS Code 30049049.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Entails obtaining a marketing authorization, requiring submission of comprehensive product information.
• Estimated Timeline: Around 7 months, depending on the application's completeness.
• Import Tariff/Duty: Belgium, as part of the EU, imposes a 0% tariff on pharmaceuticals under HS Code 30049049.

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Requires a Drug Identification Number (DIN) and an Establishment License (EL) for the importer. The foreign manufacturing site must be listed on the importer's EL.
• Estimated Timeline: The process can take several months, depending on the completeness of the application and compliance with Good Manufacturing Practices (GMP).
• Import Tariff/Duty: Canada generally applies a 0% tariff on pharmaceuticals under HS Code 30049049.

Navigating these regulatory landscapes is essential for successful market entry and sustained operations in these countries.

The demand for Irinotecan in importing countries is driven by several factors:

• Disease Prevalence: Irinotecan is primarily used in the treatment of colorectal cancer. According to the World Health Organization (WHO), colorectal cancer is among the top three most common cancers worldwide, with increasing incidence rates in many countries.

• Government Healthcare Programs: Many countries have national healthcare programs that subsidize cancer treatments, increasing accessibility and demand for drugs like Irinotecan.

• Universal Health Coverage Expansion: Efforts to expand universal health coverage in various countries have led to increased procurement of essential medicines, including cancer therapies.

• WHO Essential Medicines List Procurement: Irinotecan is included in the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement of critical drugs.

• Tender-Based Purchasing: Many healthcare systems utilize tender processes for drug procurement, ensuring competitive pricing and consistent supply of medications like Irinotecan.

With 495 buyers across 111 countries, the global reach and consistent demand for Irinotecan underscore its significance in cancer treatment protocols worldwide.

The importation of Irinotecan from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like Fresenius Kabi Deutschland GmbH (Germany) and Yusen Logistics Benelux Belgium (Belgium) function as intermediaries, procuring large quantities to supply to healthcare providers. Their purchasing patterns are characterized by bulk orders and consistent procurement schedules to maintain a steady supply chain.

• Hospital Groups: Organizations such as Pharmacie Centrale des Hôpitaux (Algeria) represent centralized procurement bodies for hospital networks. They typically engage in large-volume purchases, often through tender processes, to meet the collective needs of associated hospitals.

• Contract Manufacturers: Companies like Eugia Pharma Inc (Canada) and Eugia US LLC (United States) specialize in manufacturing pharmaceuticals on behalf of other firms. They import active pharmaceutical ingredients (APIs) like Irinotecan for formulation and packaging, adhering to stringent quality standards. Their procurement is project-based, aligning with production schedules and client demands.

• Re-exporters: Entities such as Alloga France (Netherlands) and Accord Healthcare Polska Sp. z o.o. (Poland) import pharmaceuticals with the intent to distribute them to other markets. Their purchasing behavior is influenced by global demand fluctuations and regulatory considerations in target markets.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

Importing Irinotecan into the top five importing countries involves navigating specific regulatory frameworks:

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Requires submission of a marketing authorization application, including comprehensive data on quality, safety, and efficacy.
• Estimated Timeline: Approximately 7 months, subject to completeness and compliance of the application.
• Import Tariff/Duty: As an EU member, Germany applies a standard tariff rate of 0% for pharmaceuticals under HS Code 30049049.

• Poland:
• Regulatory Authority: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).
• Import Registration Process: Involves obtaining a marketing authorization, necessitating submission of detailed documentation on the medicinal product.
• Estimated Timeline: Typically 7 months, depending on the application's complexity and accuracy.
• Import Tariff/Duty: As part of the EU, Poland imposes a 0% tariff on pharmaceuticals classified under HS Code 30049049.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Requires a marketing authorization, with submission of extensive data on the product's quality, safety, and efficacy.
• Estimated Timeline: Approximately 7 months, contingent upon the thoroughness of the application.
• Import Tariff/Duty: As an EU member state, the Netherlands applies a 0% import tariff for pharmaceuticals under HS Code 30049049.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Entails obtaining a marketing authorization, requiring submission of comprehensive product information.
• Estimated Timeline: Around 7 months, depending on the application's completeness.
• Import Tariff/Duty: Belgium, as part of the EU, imposes a 0% tariff on pharmaceuticals under HS Code 30049049.

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Requires a Drug Identification Number (DIN) and an Establishment License (EL) for the importer. The foreign manufacturing site must be listed on the importer's EL.
• Estimated Timeline: The process can take several months, depending on the completeness of the application and compliance with Good Manufacturing Practices (GMP).
• Import Tariff/Duty: Canada generally applies a 0% tariff on pharmaceuticals under HS Code 30049049.

Navigating these regulatory landscapes is essential for successful market entry and sustained operations in these countries.

The demand for Irinotecan in importing countries is driven by several factors:

• Disease Prevalence: Irinotecan is primarily used in the treatment of colorectal cancer. According to the World Health Organization (WHO), colorectal cancer is among the top three most common cancers worldwide, with increasing incidence rates in many countries.

• Government Healthcare Programs: Many countries have national healthcare programs that subsidize cancer treatments, increasing accessibility and demand for drugs like Irinotecan.

• Universal Health Coverage Expansion: Efforts to expand universal health coverage in various countries have led to increased procurement of essential medicines, including cancer therapies.

• WHO Essential Medicines List Procurement: Irinotecan is included in the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement of critical drugs.

• Tender-Based Purchasing: Many healthcare systems utilize tender processes for drug procurement, ensuring competitive pricing and consistent supply of medications like Irinotecan.

With 495 buyers across 111 countries, the global reach and consistent demand for Irinotecan underscore its significance in cancer treatment protocols worldwide.